DaVita Inc
DaVita is a kidney-care company built around outpatient dialysis, integrated kidney care management, and related ancillary services. It also operates international dialysis centers and smaller businesses such as clinical research, transplant software, and venture investments that support its core renal-care platform.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIn-center dialysis and related clinical services for patients with end-stage kidney disease.
Care management, analytics, and value-based programs for CKD and ESKD patients under payer contracts.
Outpatient dialysis centers and administrative services across markets outside the United States.
Clinical research, transplant software, and other kidney-care-adjacent services.
Customers
DaVita serves patients with chronic kidney disease and end-stage kidney disease, but the paying customers are often health plans, Medicare Advantage plans, government programs, and transplant centers. Its ancillary businesses also sell to pharmaceutical sponsors, device developers, and transplant care teams, which broadens the revenue base beyond direct dialysis reimbursement.
Patients with ESKD who receive recurring outpatient dialysis treatments in DaVita centers.
Payers that buy IKC services to manage CKD/ESKD populations and reduce total medical cost.
Managed-care customers that use value-based kidney care and disease management arrangements.
Drug and device companies that contract with DCR for study design, recruitment, and trial execution.
Providers that use MedSleuth to coordinate transplant candidates, physicians, and care teams.
Strategy
DaVita is pushing beyond traditional dialysis into integrated, value-based kidney care while keeping its core treatment network central to the model. It is also expanding adjacent services such as transplant software, clinical research, and venture-backed innovation to deepen patient relationships and create optionality around kidney disease management.
Value-based care can deepen payer relationships and diversify reimbursement beyond pure dialysis volume.
Clinical research, transplant software, and internal software tools extend the platform and create cross-sell opportunities.
International centers provide growth and diversification, but require disciplined execution in local markets.
Geography
DaVita’s business is concentrated in the United States, where its dialysis, IKC, and ancillary platforms are managed and where most strategic and regulatory exposure sits. It also runs a meaningful international dialysis network, with 585 outpatient centers in 14 countries outside the U.S. as of year-end 2025, making non-U.S. operations an important operational and currency/regulatory exposure.
Risks
DaVita faces reimbursement, regulatory, and execution risk because its core services are delivered in a highly regulated healthcare environment and depend on payer and government funding. The company also has meaningful operational risk from supply chain disruptions, third-party vendors, cybersecurity-related billing interruptions, and the possibility that newer strategic initiatives may not become profitable.
- Supply chain shortages and service disruptionsImpact: HighLikelihood: High
Critical clinical and other supplies are needed to maintain dialysis continuity; shortages can increase expense and slow growth.
Exposure: Home-based dialysis and clinical supply chain
- Third-party service provider dependenceImpact: HighLikelihood: High
Outsourced services can create loss of control, service interruption, and replacement-cost risk.
Exposure: Vendor-managed business functions
- Regulatory and reimbursement pressureImpact: HighLikelihood: High
Dialysis and IKC economics depend on payer rates, government programs, and compliance with healthcare rules.
Exposure: U.S. dialysis and integrated kidney care
- Cybersecurity and billing disruptionImpact: HighLikelihood: Medium
A billing/collection system disruption can increase days sales outstanding and delay cash conversion.
Exposure: U.S. accounts receivable and revenue cycle
- Strategic initiative execution riskImpact: MediumLikelihood: High
New offerings may require significant investment and may not reach profitability on schedule, or at all.
Exposure
Accounting
Judgemental itemsRevenue is recognized as services are provided, with estimates of net realizable amounts affecting reported revenue and receivables.
Impact: Affects timing of revenue and accounts receivable valuation
IKC includes fixed-fee, shared-savings, pay-for-performance, and capitation structures that require judgment on earned revenue.
Impact: Can create quarter-to-quarter variability in recognized revenue
Billing and collection timing, including cybersecurity-related disruption, can change DSO and cash conversion.
Impact: Affects operating cash flow and collectability assumptions
The company must test goodwill when circumstances change, including reimbursement, market, or partner-related shifts.
Impact: Could lead to non-cash impairment charges
Remeasurements and discrete tax events can materially affect reported earnings and effective tax rates.
Impact: Creates volatility in net income attributable to DaVita Inc.
Similar listed companies
Publicly listed companies with a comparable business focus.
IQVIA Holdings, Inc
IQV · Services-Commercial Physical & Biological Research
Davion Healthcare PLC
DAVI · Surgical & Medical Instruments & Apparatus
Davion Healthcare Plc is an Ireland-based healthcare company focused on developing and commercialising healthcare technologies and products.
Baxter International Inc
BAX · Surgical & Medical Instruments & Apparatus
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Akebia Therapeutics, Inc.
AKBA · Pharmaceutical Preparations
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications.
LivaNova PLC
LIVN · Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions.
Last updated: 24/09/2026